Table 1.
Mean (SD) baseline demographics
| Regimen | n | Age (years) | Weight (kg) | Height (cm) | BMI (kg m−2) | Race (%White) |
|---|---|---|---|---|---|---|
| 0.7 mg s.c. | 4 | 32.3 (9.1) | 78.7 (8.82) | 177.4 (4.1) | 25.0 (2.64) | 50 |
| 2.1 mg s.c. | 4 | 30.5 (3.4) | 80.5 (3.61) | 180.7 (7.8) | 24.8 (2.87) | 0 |
| 7 mg s.c. | 6 | 26.5 (6.3) | 79.4 (10.7) | 178.0 (8.0) | 25.1 (3.58) | 33 |
| 21 mg s.c. | 6 | 24.2 (3.1) | 76.4 (11.1) | 174.5 (5.2) | 25.2 (3.87) | 50 |
| 70 mg s.c. | 6 | 28.3 (6.2) | 72.7 (10.0) | 172.1 (3.8) | 24.5 (3.11) | 33 |
| 210 mg s.c. | 6 | 29.5 (5.9) | 80.3 (12.0) | 174.6 (5.4) | 26.4 (4.06) | 50 |
| 70 mg i.v. | 6 | 29.0 (4.9) | 82.6 (6.27) | 179.6 (3.7) | 25.7 (2.39) | 50 |
| 210 mg i.v. | 6 | 28.5 (7.8) | 84.4 (22.3) | 181.4 (15.2) | 25.4 (4.43) | 83 |
| 420 mg i.v. | 6 | 29.8 (5.7) | 79.9 (11.3) | 179.8 (7.5) | 24.7 (2.76) | 0 |
| 210 mg s.c. (UC) | 3 | 37.3 (5.1) | 66.5 (11.0) | 168.0 (3.1) | 23.5 (2.98) | 67 |
| Combined | 53 | 29.0 (6.2) | 78.7 (11.8) | 176.9 (7.8) | 25.1 (3.17) | 42 |
| Placebo | 19 | 29.9 (6.5) | 82.7 (12.1) | 176.3 (6.0) | 26.7 (4.24) | 63 |
| All | 72 | 29.3 (6.2) | 79.7 (12.0) | 176.7 (7.3) | 25.5 (3.52) | 47 |
Healthy subjects: all male; UC subjects: two female and one male were AMG 181-treated, one male received placebo. Combined = all AMG 181-treated, including healthy and UC subjects; Placebo = all placebo treated, including healthy and one UC subjects. BMI = body mass index; SD = standard deviation; s.c. = subcutaneous; i.v. = intravenous; UC = ulcerative colitis.